Cannabidiol (CBD) Oil Capsules + Sunflower Lecithin Oil in Capsule
Phase 3UNKNOWN 0 watching 0 views this week📈 Rising
72
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Generalized Anxiety Disorder
Conditions
Generalized Anxiety Disorder, Social Anxiety Disorder, Panic Disorder, Agoraphobia
Trial Timeline
Dec 15, 2021 → Feb 1, 2024
NCT ID
NCT03549819About Cannabidiol (CBD) Oil Capsules + Sunflower Lecithin Oil in Capsule
Cannabidiol (CBD) Oil Capsules + Sunflower Lecithin Oil in Capsule is a phase 3 stage product being developed by Tilray for Generalized Anxiety Disorder. The current trial status is unknown. This product is registered under clinical trial identifier NCT03549819. Target conditions include Generalized Anxiety Disorder, Social Anxiety Disorder, Panic Disorder.
Hype Score Breakdown
Clinical
27
Activity
18
Company
5
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03549819 | Phase 3 | UNKNOWN |
Competing Products
20 competing products in Generalized Anxiety Disorder
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| atomoxetine + placebo | Eli Lilly | Phase 2/3 | 65 |
| Satralizumab | Chugai Pharmaceutical | Phase 3 | 77 |
| Perampanel | Eisai | Pre-clinical | 23 |
| Perampanel + Placebo comparator | Eisai | Phase 3 | 77 |
| zonisamide | Eisai | Pre-clinical | 23 |
| Fycompa | Eisai | Pre-clinical | 23 |
| Fycompa | Eisai | Pre-clinical | 23 |
| Perampanel | Eisai | Phase 3 | 77 |
| Perampanel | Eisai | Pre-clinical | 23 |
| Cenobamate | Ono Pharmaceutical | Phase 3 | 77 |
| Duloxetine + Placebo | Eli Lilly | Phase 3 | 77 |
| Duloxetine + Placebo | Eli Lilly | Approved | 85 |
| Ixekizumab | Eli Lilly | Approved | 85 |
| eszopiclone + eszopiclone + Placebo | Sumitomo Pharma | Phase 2 | 52 |
| Usual dose treatment of Tandospirone + Comparative high dose of tandospirone treatment | Sumitomo Pharma | Approved | 85 |
| ABBV-932 + Placebo for ABBV-932 + Antidepressant Therapy (ADT) | AbbVie | Phase 2 | 52 |
| Cariprazine 0.75 mg/day + Cariprazine 1.5 mg/day + Cariprazine 3.0 mg/day | AbbVie | Phase 2 | 52 |
| ABBV-932 + Placebo | AbbVie | Phase 1 | 33 |
| Escitalopram | AbbVie | Approved | 85 |
| Adalimumab | AbbVie | Phase 3 | 77 |
Other Products from Tilray
TN-TC11M2 oral capsules (THC 2.5 mg/CBD 2.5 mg) + TN-C200M2 oral capsules (CBD 200 mg)Phase 2
47
High THC/Low CBD Cannabis + High THC/High CBD Cannabis + Low THC/Low CBD CannabisPhase 2
47
TN-TC11G + Temozolomide Oral ProductPhase 1/2
36
Cannabidiol + PlacebosPhase 1/2
36
Phytocannabinoid cannabidiol (CBD)Phase 1/2
36